Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

l.

The pivotal study is expected to commence in the first quarter of 2009, with a potential projected BLA filing in late 2010. BioVex is currently commissioning its GMP manufacturing facility in Woburn, Massachusetts, which is intended to provide product for Phase III studies and launch.

Dr Robert Coffin, Chief Technology Officer for BioVex, said:

"This agreement with the FDA for the pivotal Phase III study design for OncoVEX(GM-CSF) in melanoma, which uses a very similar design as successfully employed in Phase II, is a significant event for BioVex. We believe the Phase II study results relating to durable objective response provide a sound basis on which to proceed with confidence to Phase III where the primary objective is to demonstrate a statistically significant increase in durable objective responses as compared to control therapy. We look forward to the presentation of the Phase II results at ASCO, and thereafter to the initiation of the pivotal study."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX(GM-CSF), is an unpartnered, first-in-class oncolytic, or cancer destroying virus technology. OncoVEX(GM-CSF) works by: 1) replicating and spreading within solid tumors, causing the death of cancer cells; while 2) stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. Based on the strength of the clinical data generated to date, coupled with a benign side effect profile, BioVex believes OncoVEX(GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors.

OncoVEX(GM-CSF) is currently complet
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues ("BioLife" or the "Company"), announced that ... MicroCap Conference. The Company is scheduled to ... May 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... 20, 2011 The U.S. Food and Drug Administration ... development and approval of an artificial pancreas system to ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the pancreas produces little or no insulin, a hormone ...
... YORK, June 20, 2011 Andrew Technologies, LLC the ... Tom Albright as Chief Executive Officer and Board Member ... with almost 3 decades of drug, biologic, device and ... held leadership positions at Allergan (the world,s leading aesthetic ...
Cached Medicine Technology:FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3Andrew Technologies Names Tom Albright CEO and Board Member 2
(Date:5/25/2015)... ProDrop Light Show allows users to now have ... a click of a mouse. Users have full control over angle ... Cut Pro X. , ProDrop Light Show gives users 30 fully ... much more leaving infinite possibilities all within Final Cut Pro X. ... presets, users can apply their very own media files or text ...
(Date:5/25/2015)... Tunstall Americas announces major investment in ... of service to its Medical Answering Service customers. ... of resources, Tunstall now provides a seamless transition between ... Service to ensure superior patient satisfaction. , ... over $10 million in expanded facilities and the latest ...
(Date:5/24/2015)... Pacific Prime has announced that they have launched the second ... of individual international health insurance. Titled: The Cost of Health Insurance ... health insurance in six top expat destinations, which are also popular ... Kong , Singapore , China , ... UK , Article 2 presents an in-depth look at ...
(Date:5/24/2015)... 24, 2015 For people who are ... Enterokinase Industry, 2009-2019 Market Research Report would be an ... exhaustive study on the present market scenario of this ... the growing Chinese market of this industry. The report ... status of the manufacturers in this industry. The report ...
(Date:5/24/2015)... NH (PRWEB) May 24, 2015 ... leather, launches “InkGard™ Plus” – a classic, rugged ... the polymer allowing difficult stains, including ink, to ... 16 different colors suitable for corporate, healthcare, hospitality ... in line with EnviroLeather’s goal of developing products ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2
... Thursday it had maintained authorisation of weight-loss pill Acomplia in ... from people suffering from depression. ,A panel ... in June that the dieting treatment, which can also be ... thoughts as a side-effect. ,The maker of the ...
... went a little wild at a club. ,The ... in Bucharest, Romania after a gig and spent a whopping amount ... girls in his party so he reportedly asked where the women ... most expensive beverages and a group of girls who arrived after ...
... this weeks BMJ is set to re-open the debate over ... Lancet recently published a study on repeat infant deaths in ... in the same family are natural. ,These ... proportion of repeat cot deaths were probably homicide. Yet the ...
... behind her battle with Insomnia is her songs. ... the sleep disorder, because her songs keep her awake at night. ... and hits strike her when she's trying to get to some ... down or record them on the spot, which results in a ...
... to overtake the United States as the world's biggest user ... according to a government report seen Thursday. ... via broadband and another 40 million who regularly log on ... the government-controlled China Internet Network Information Center. ,The ...
... in Chennai has created history by successfully conducting a ... using the cord blood cells from an American ... cost internationally. ,Howard Kafeero from Uganda suffered ... have been fatal. Seven months ago, he was brought ...
Cached Medicine News:Health News:New Analysis Puts Cot Death Under Scrutiny Once Again 2Health News:China Closing in on US for Highest Number of Web-users 2Health News:Chennai Hospital Conducts Bone Marrow Transplantation Successfully 2
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 8-11; contains 1 bottle each of 20 nm and 40 nm Naked Gold...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD...
Medicine Products: